OKYO Pharma Ltd - New
Research OKYO Pharma Ltd - New (OKYO) on Bullrun: market cap USD 81.87M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerOKYO
- ExchangeNASDAQ
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 81.87M
- Financial periodQ1 2026
Valuation Snapshot
latest market cap is USD 81.87M.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 81.87M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 79.60M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 39.03M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 58.83M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 41.58M | n/a | n/a | n/a |
About OKYO Pharma Ltd - New
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is OKYO Pharma Ltd - New's market cap?
OKYO Pharma Ltd - New's market capitalization is USD 81.87M.
What does OKYO Pharma Ltd - New do?
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201 for the treatment acute and chronic ocular pain.